Dew, NVS owns 1/3 of Roche. Doesn't that create a conflict of interest ? ----------------- In their sights are current blockbuster biotech treatments from companies including Roche and Amgen (AMGN). ----------------- I mean, any gain by Sandoz/Mnta on Roche with generic biologics will be deducted from the loss of Roche mkt cap ? Perhaps the FOB partner(s) for mnta will have to come from another company than NVS; there are more than one, luckily.